louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04350047: Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus: Resection Without Thoracotomy
Official title: Resection of Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus Without Thoracotomy: A Case Series and Literature Review.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Cell Carcinoma Stage III
Keywords: Renal cell carcinoma
Tumor thrombus
Inferior vena cava
level IV
Lead sponsor: Attikon Hospital
Sponsor class: OTHER
First posted: 2020-04-16
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Among all patients with renal cell carcinoma operated in Attikon University Hospital, the ones with level IV tumor thrombus were included in the study.

Brief summary: Assessment of short-term outcomes of radical nephrectomy combined with IVC thrombectomy with a novel technique without thoracotomy: single center case series.

Detailed description: Assessment of the 30-day mortality and major complications as well as long-term oncological outcomes of three patients undergoing radical nephrectomy combined with inferior vena cava (IVC) thrombectomy with a novel technique without thoracotomy for renal cell carcinoma with IVC level IV thrombus. This is a retrospective case series carried out at Attikon University Hospital between January 2018 to March 2020.

Eligibility criteria: Inclusion Criteria:

* Adult patients
* Documented radiological and/or pathological diagnosis of renal cell carcinoma with level IV tumor thrombus

Exclusion Criteria:

* American Anesthesia Association (ASA) Class V and/or any contraindications to general anesthesia

Primary outcomes:
measure: Short term mortality rate
timeFrame: 30 days
Secondary outcomes:
measure: Short term major complications' rate
timeFrame: 30 days
measure: Recurrence rate
timeFrame: 27 months
Other outcomes:
Locations:
city: Chaidari
country: Greece
facility: Attikon University Hospital
Study officials:
affiliation: Attikon Hospital
name: Nikolaos Arkadopoulos, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03276247: Iron Status in Women of Reproductive Age Reproductive Age
Official title: Ethnic and Genetic Factors of Iron Status in Women of Reproductive Age
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iron Metabolism Disorders
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
Collaborators: name: Weill Medical College of Cornell University
First posted: 2017-09-08
Enrollment: 22042
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 44
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care women included in the HEIRS study.

Brief summary: Analyzed iron status, HFE mutations and ethnicity for women in five primary care centers in the United States and Canada using de-identified data from the HEIRS study.

Detailed description: HEIRS included a cross-sectional screening study of 101,168 patients, 25 years of age or older, in the primary care setting. Participants were recruited from four centers in the U.S .and one in Canada from February 2001 to February 2003. We will evaluate results for women aged 25-44 years of age who are self-reported as Asian, Black, Hispanic or White. The lower detection limit for the serum ferritin (SF) assay in the HEIRS study was 15 μg/L and therefore the definition of iron deficiency will be SF concentration ≤ 15 μg/L. Elevated SF concentrations, possibly indicative of elevated iron stores, will be classified by two definitions: 1) SF concentration \> 300 μg/L and 2) SF \>200 μg/L in combination with TSAT \>45%. Proportions will be compared by Pearson's chi-square. Logistic regression models will be used to identify independent associations with measures of iron deficiency and elevated iron stores.

Eligibility criteria: Inclusion Criteria:

1. primary care women included in the HEIRS study with in the age range of this study
2. Self designation as Asian American, African American, Hispanic American or White.

Exclusion Criteria:

1. Age \>44 years
2. Self-described ethnicity other in than inclusion criterion 2.

Primary outcomes:
measure: Elevated serum ferritin
timeFrame: One measurement was made at the time of recruitment and this is the measurement that will be analyzed.
measure: Elevated serum ferritin and transferrin saturation
timeFrame: One measurement was made at the time of recruitment and this is the measurement that will be analyzed.
measure: Iron deficiency
timeFrame: One measurement was made at the time of recruitment and this is the measurement that will be analyzed.
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago
name: Victor R Gordeuk, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gordeuk VR, Brannon PM. Ethnic and genetic factors of iron status in women of reproductive age. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1594S-1599S. doi: 10.3945/ajcn.117.155853. Epub 2017 Oct 25.
Clinical trial NCT02848547: Post Trial Analysis of a Primary Prevention Study in Asian Indians
Official title: The Role of Information Technology in the Prevention of Type 2 Diabetes - An Extended Follow-up Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Lead sponsor: India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Sponsor class: OTHER
First posted: 2016-07-28
Enrollment: 537
Sex: ALL
Minimum age (years): 40
Maximum age (years): 63
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants randomized (n=537) in the primary study NCT00819455.

Brief summary: An extended follow-up study of NCT00819455 conducted 5 years post randomization. In this study we estimate the incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme. This will provide comparison of the progression to diabetes among group motivated through text messages and the group educated only during enrollment. A total of 537 participants were enrolled in the primary study and are invited to participate in a follow-up visit 3 years post active trial period.


Eligibility criteria: Inclusion Criteria:

Participants of the primary prevention programme - NCT00819455.

Exclusion Criteria:

Unwilling for participation

Primary outcomes:
measure: Incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme.
timeFrame: Two years
Secondary outcomes:
measure: Long-term impact of healthy lifestyle through mobile phone based text messaging
timeFrame: Two years
Other outcomes:
Locations:
Study officials:
References:
citation: Nanditha A, Snehalatha C, Raghavan A, Vinitha R, Satheesh K, Susairaj P, Simon M, Selvam S, Ram J, Naveen Kumar AP, Godsland IF, Oliver N, Johnston DG, Ramachandran A. The post-trial analysis of the Indian SMS diabetes prevention study shows persistent beneficial effects of lifestyle intervention. Diabetes Res Clin Pract. 2018 Aug;142:213-221. doi: 10.1016/j.diabres.2018.05.042. Epub 2018 May 31.
Clinical trial NCT04993547: Cluster-RCT Collective Nasopharyngeal COVID-19 Testing Amongst Pupils
Official title: Peers' and Parent's Presence During Collective Nasopharyngeal COVID-19 Testing Amongst Pupils: A Cluster-Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peer Group
Parents
Keywords: Public Health
Pediatric
Nasopharyngeal
Collective testing
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2021-08-06
Enrollment: 952
Sex: ALL
Minimum age (years): 30
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?

Detailed description: In order to control the outbreak of cluster infections on school during the COVID-19 pandemic, regular rounds of collective nasopharyngeal swab testing were organized. However, it is unclear under which circumstances nasopharyngeal swab testing is better accepted by young children. Due to the closing of schools, and the different logistic situations in schools, a natural pragmatic RCT formed. In some cases, children could observe their peers before having their own test, while for others the view was blocked. Also, sometimes parents would be present during a test procedure when the school was closed, while they were not present when the school was open. To date, it is unclear whether these two variable elements influence a child's resistance to be tested. Therefore a cluster-randomized controlled trial with testing site as the unit of randomisation will be set-up. Four conditions will be tested. On the individual level, the resistance of their peers before their own testing will be taken into account. The aim of the study is to compare whether (1) the visibility of nasopharyngeal swab testing on their peers and (2) the presence of their parents impacts a child's resistance towards the test. Additionally, the impact of whether or not their peers resisted the test impact predicts the likelihood of their own resisting behaviour.

Eligibility criteria: Inclusion Criteria:

* undergoing a nasopharyngeal COVID-19 swab test

Exclusion Criteria:

-

Primary outcomes:
measure: test resistance
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: Ghent University Hospital
Study officials:
affiliation: University Hospital, Ghent
name: Simon Malfait
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00689247: To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305
Official title: A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) After Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: AZD1305
ADME
pharmacokinetic
Absorption
distribution
metabolism
excretion
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-06-03
Enrollment: 10
Sex: MALE
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* A body mass index (BMI=weight/height2) of 19 to 30 kg/m2

Exclusion Criteria:

* Potassium outside normal reference values
* ECG findings outside normal range

Primary outcomes:
measure: Pharmacokinetic variables
timeFrame: During all dosing visits
Secondary outcomes:
measure: Adverse events, vital signs, ECG, laboratory variables and physical examination
timeFrame: During the study
Other outcomes:
Locations:
city: Macclesfield
country: United Kingdom
facility: Research Site
state: Cheshire
Study officials:
affiliation: AstraZeneca R&D, Mölndal, Sweden
name: Helen Lunde, MD
role: STUDY_DIRECTOR
affiliation: AstraZeneca CPU Alderley Park, United Kingdom
name: Raj Chetty, MBBS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00219947: Viral and Host Factors in the Transmission and Pathogenesis of HIV
Official title: Viral and Host Factors in the Transmission and Pathogenesis of HIV
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: HIV Infections
Keywords: HIV Infection
Acute HIV Infection
Primary HIV Infection
Acute Seroconversion Syndrome
Lead sponsor: Rockefeller University
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 600
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects are either referred by primary health care providers, self-referred, or may be seeking enrollment in other ADARC clinical trials in the NYC area.

Brief summary: To study the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

The data collected are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines.

Detailed description: This phlebotomy protocol permits the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

Participants will have from 10 to 60 ml (approximately 1 to 4 tablespoons) of blood drawn for one or all of the following tests:

* T cell subset enumeration
* Serologic reactivity with HIV antigens
* Viral load assays by bDNA, PCR, or RT-PCR
* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
* HIV-1 Resistance Testing

These data are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines

Eligibility criteria: Inclusion Criteria:

recently infected with HIV-1 HIV-1 negative, and at high risk for infection

Exclusion Criteria:

none

Primary outcomes:
measure: Participants are tested for HIV-1 RNA levels, the presence of antibodies to HIV antigens, and T cell subsets
timeFrame: first visit
Secondary outcomes:
measure: Data will be used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment
timeFrame: first visit
Other outcomes:
Locations:
city: New York
country: United States
facility: Aaron Diamond AIDS Research Center (ADARC)
state: New York
city: New York
country: United States
facility: Rockefeller University Hospital
state: New York
Study officials:
affiliation: Rockefeller University
name: Martin M Markowitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00940147: Early Endoscopic Indicators for OACs After Lung Transplantation: Development of a Novel Mucosal Healing Score
Official title: Early Indicators for Obstructive Airway Complications After Lung
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Airway Complication Which Require Any Intervention
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
First posted: 2009-07-15
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: LTx 01.2007-05.2009

Brief summary: Airway complications are a significant cause of morbidity after lung transplantation (LTx). Bronchoscopic evaluation may help to identify risk factors for requiring interventions later.

Detailed description: The investigators evaluated lung transplant recipients prospectively. Adult patients surviving 90 day after LTx will be included. The investigators propose a classification of airway healing based on the endoscopic bronchial appearances at days 7, 14, 21, 90, 180 and 365 after LTx. A score system including mucosal healing, full tissue necrosis (=dehiscence), lose sutures, fibrin plugs, polyps and malacia will be developed (max. score 8 points/date). Endoscopic findings will be correlated with the development of obstructive airway complications (OAC, requiring \>1 intervention). Afterwards the new score system will be applied prospectively in the patients.

Eligibility criteria: Inclusion Criteria:

* 3 month survivor after LTx
* no OAC

Exclusion Criteria:

-

Primary outcomes:
measure: Primary endpoint of this study was any obstructive airway complication (AC) which required desobliterative intervention.
timeFrame: 1 year
Secondary outcomes:
measure: secondary endpoint included anastomosis-related death.
timeFrame: 1 year
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Hannover Medical School
Study officials:
References:
Clinical trial NCT00573547: Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease
Official title: A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Depression
Keywords: depression
chronic renal failures
end stage renal disease
Lead sponsor: Creighton University
Sponsor class: OTHER
First posted: 2007-12-14
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

Detailed description: Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic renal failure and end stage renal disease
* Ongoing need for regular dialysis treatment
* Diagnosis of depression based on DSMIV
* Age tween 19-65 years

Exclusion Criteria:

* Inability to provide informed consent
* Medically or psychiatrically unstable, as defined by requiring inpatient treatment
* Pregnancy, nursing or refusal to use a reliable method of birth control in women
* Patients with known allergy to fluoxetine, or previous treatment failure of fluoxetine

Primary outcomes:
measure: Determine the efficacy and tolerability of once-weekly fluoxetine in patients with End Stage Renal Disorder who have been diagnosed with depression
timeFrame: Patients will come in for once weekly visits for 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Omaha
country: United States
facility: Creighton Department of Psychiatry
state: Nebraska
city: Omaha
country: United States
facility: Creighton University Department of Psychiatry
state: Nebraska
Study officials:
affiliation: Creighton University Department of Psychiatry
name: Syed P Sattar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05239247: Effects of Eldoa Versus Meckenzie Exercise on Non-specific Low Back Pain Patients
Official title: Effects of Eldoa Versus Meckenzie Exercise on Non-specific Low Back Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-02-14
Enrollment: 48
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the effects of Eldoa and Mckenzie exercises in posture. To determine the effects of Eldoa and Mckenzie exercises in ROM.

Detailed description: To determine the effects of Eldoa and Mckenzie exercises in pain. To determine the effects of Eldoa and Mckenzie exercises in Quality of life.

Eligibility criteria: Inclusion Criteria:

* Gender (Female)
* Age (40-69)
* NPRS (Grade \<3)
* Chronic pain (more than or equal to 3 months)
* Restricted ROM
* Lumbar straightening

Exclusion Criteria:

* Any other orthopedic or neurological condition of hip or lumbar spine.
* sign and symptoms of lower motor neuron disease.
* Current use of medication prescribed for pain.
* Radiculopathy.
* malignancy.
* Fracture.
* Lumbar trauma.
* Disc pathology

Primary outcomes:
measure: lumbar ROM by inclinometer.
timeFrame: 12 days
measure: Lumbar Posture by flexicurve ruler.
timeFrame: 12 days
Secondary outcomes:
measure: pain on Numeric pain rating scale.
timeFrame: 12 days
measure: functional outcome by Oswestry low back pain disability questionnaire.
timeFrame: 12 days
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Rawal General And Dental Hospital
state: Federal
Study officials:
affiliation: Riphah International University
name: Waqar Ahmed Awan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01162447: Comparison of Bone Morphogenetic Protein-4 (BMP-4) and 7 Levels Between Control and Polycystic Ovarian Syndrome (PCOS) Patients.
Official title: Comparison of Bone Morphogenetic Protein-4 and -7 Levels (BMP-4 and 7) in the Serum, Ovarian Follicle Aspirates and Ovarian Organ Culture Supernatants Between Healthy Controls and Patients With Polycystic Ovarian Syndrome (PCOS).
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Polycystic Ovarian Syndrome
Keywords: BMP- 4 and 7, polycystic ovarian syndrome
Lead sponsor: V.K.V. American Hospital, Istanbul
Sponsor class: OTHER
First posted: 2010-07-14
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who present to the women's health center of American Hospoital for complaints due to polcystic ovarian syndrome will be enrolled. Age-matched healthy subjects will be chosen for comparison.

Brief summary: The investigators aim to compare the levels of bone morphogenetic protein-4 and -7 (BMP-4 and 7) in blood, follicular fluid and ovarian organ culture supernatant obtained from healthy subjects and polycystic ovarian syndrome (PCOS) patients.

Detailed description: Female patients at ages 20-35 diagnosed with polycystic ovarian syndrome and age-matched healthy control subjects will be enrolled in this study.

Blood samples will be obtained at early follicular phase during doctor's visit from PCOS patients and control subjects.If the patient is amenorrheic at the time of visit, both random blood samples and another sample at early follicular phase after induction of withdrawal bleeding with progesterone.

Follicular fluids will be retrieved during oocyte pick-up procedure in patients undergoing assisted reproduction for PCOS and control IVF patients whose infertility is not PCO related.

Samples from ovaries will be collected at operation from PCOS patients and control subjects if they already undergo any gynecologic laparotomi operations.

Collected samples will be cultured for 7 days and BMP-4 and -7 levels will be measured in the culture fluid of the samples using ELISA method.

Eligibility criteria: Inclusion Criteria:

* Healthy subjects and PCOS patients at ages 20-35 will be recruited for the study.

Exclusion Criteria:

* Those with any metabolic or endocrine problems other than PCOS will be excluded from the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: American Hospital Women's Health Center
Study officials:
affiliation: VKV American Hospital Women's Health center
name: Bulent Urman, MD
role: STUDY_DIRECTOR
References: